Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
Open Access
- 2 July 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (7) , e002896
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk–benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs.Keywords
Funding Information
- Project Data Sphere
This publication has 32 references indexed in Scilit:
- Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean MassDiabetes, 2018
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint InhibitorsDiabetes, 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionThe Oncologist, 2018
- Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.Journal of Clinical Oncology, 2018
- Comprehensive analysis of the clinical immuno-oncology landscapeAnnals of Oncology, 2017
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJournal for ImmunoTherapy of Cancer, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysisOncoImmunology, 2017
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitisNature Communications, 2016